Список литературы

25. Kukla M, Adrych K, Dobrowolska A, Mach,T, Reguła J, Rydzewska G. Guidelines for Clostridium difficile infection in adults. Gastroenterology Rev 2020; 15 (1): 1–21. doi: 10.5114/pg.2020.93629

26. Guh AY, Kutty PK. Clostridioides difficile Infection. Ann Intern Med. 2018;169(7):ITC49-ITC64. doi: 10.7326/AITC201810020

27.   Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021;116(6):1124-1147. doi: 10.14309/ajg.0000000000001278. 2022;28(12):1204-1219. doi: 10.3748/wjg.v28.i12.1204

28. Mamieva Z, Poluektova E, Svistushkin V, Sobolev V, Shifrin O, Guarner F, Ivashkin V. Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations? World J Gastroenterol. 2022;28(12):1204-1219. doi: 10.3748/wjg.v28.i12.1204

29.  Kampouri E, Croxatto A, Prod’hom G, Guery B. Clostridioides difficile Infection, Still a Long Way to Go. J Clin Med. 2021;10(3):389. doi: 10.3390/jcm10030389

30.  Шелыгин Ю.А., Алёшкин В.А., Сухина М.А., Миронов А.Ю., Брико Н.И., Козлов Р.С. и соавт. Клинические рекомендации национальной ассоциации специалистов по контролю инфекций, связанных с оказанием медицинской помощи и общероссийской общественной некоммерческой организации «ассоциации колопроктологов россии» по диагностике, лечению и профилактике clostridium difficile-ассоциированной диареи (CDI). Колопроктология, 2018;65(3):7-23. doi:  10.33878/2073-7556-2018-0-3-7-23

31.  C.Carroll Karen, Mizusawa Masako. Laboratory Tests for the Diagnosis of Clostridium difficile. Clin Colon Rectal Surg. 2020;33(2):73-81. doi: 10.1055/s-0039-3400476

32.  Драпкина О.М., Лазебник Л.Б., Бакулин И.Г., Журавлева М.С., и др. Инфекция Clostridioides difficile: диагностика, лечение и профилактика Клинические рекомендации Российского научного медицинского общества терапевтов, Научного общества гастроэнтерологов России, Общества гастроэнтерологов и гепатологов «Северо-Запад». Экспериментальная и клиническая гастроэнтерология. 2023;(2):4-32. https://doi.org/10.31146/1682-8658-ecg-210-2-4-32

33. Sucher A, Biehle L., Smith A., Tran C. Updated Clinical Practice Guidelines for C difficile Infection in Adults. Allana Sucher et al., US Pharmacist, 46 (12), 2021: HS10- HS16

34. Mattana M, Tomasello R, Cammarata C, Di Carlo P, Fasciana T, Giordano G, Lucchesi A, Siragusa S, Napolitano M. Clostridium difficile Induced Inflammasome Activation and Coagulation Derangements. Microorganisms. 2022 Aug 10;10(8):1624. doi: 10.3390/microorganisms10081624. PMID: 36014040; PMCID: PMC9416296.

35. Iffland, A.; Zechel, M.; Lewejohann, J.-C.; Edel, B.; Hagel, S.; Hartmann, M.; Löffler, B.; Rödel, J. Experience with PCR Testing for Enteric Bacteria and Viruses of Emergency Department Patients with Acute Gastroenteritis: Are There Implications for the Early Treatment of Clostridioides difficile Infection? Antibiotics 2024, 13, 243. https://doi.org/10.3390/ antibiotics13030243

36. Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database of Systematic Reviews. 2017;3(3): CD004610. doi: 10.1002/14651858.CD004610.pub5

37. Bass SN, Lam SW, Bauer SR, Neuner EA. Comparison of oral vancomycin capsule and solution for treatment of initial episode of severe Clostridium difficile Infection. J Pharm Pract. 2015;28(2):183-188. doi: 10.1177/0897190013515925

38 uon C, Wannier R, Sterken D, Fang MC., Wolf J, Prasad PA. Are Antimotility Agents Safe for Use in Clostridioides difficile Infections? Results From an Observational Study in Malignant Hematology Patients. Mayo Clin Proc Inn Qual Out. 2020;4(6):792-800. doi:: 10.1016/j.mayocpiqo.2020.06.005

39. Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan – Taber S, Fitts D, Gelone SP, Broom C, Davidson DM. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59:345–354 . doi:  10.1093/cid/ciu313

40.     Waqas M, Mohib K, Saleem A, LNU M, Arjumand S, Khalil HH, Nosheen R, Abbas S, Maqsood KM, Abbas K. Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection. Cureus. 2022 ;14(4):e24140. doi: 10.7759/cureus.24140.

41.  Sirbu BD, Soriano MM, Manzo C, Lum J, Gerding DN, Johnson S. Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection. Clin Infect Dis. 2017;65(8):1396–1399. doi: 10.1093/cid/cix529

42.  Major G, Bradshaw L, Boota N, Sprange K, Diggle M, Montgomery A, Jawhari A, Spiller RC. Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial. Gut. 2019; 68(7):1224–1231. doi: 10.1136/gutjnl-2018-316794

43.  Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, Du Pont HL. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011;66(12):2850-5. doi: 10.1093/jac/dkr377.

44.  Ng Qin X, Loke W, Foo NX, Yin M, Yeo WS, Soh AYS. A systematic review of the use of rifaximin for Clostridium difficile infections. Anaerobe. 2019;55:35-39. doi: 10.1016/j.anaerobe.2018.10.011

45.  Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254(3):423-7; discussion 427-9. doi: 10.1097/SLA.0b013e31822ade48

46.  Juo YY, Sanaiha Y, Jabaji Z, Benharash P. Trends in Diverting Loop Ileostomy vs Total Abdominal Colectomy as Surgical Management for Clostridium difficile Colitis. JAMA Surg. 2019;154(10):899-906. doi: 10.1001/jamasurg.2019.2141

47.  Wang JW, Kuo CH, Kuo FC, Wang YK, Hsu WH, Yu FJ et al. Fecal microbiota transplantation: Review and update. J Formos Med Assoc. 2019;118 Suppl 1:S23-S31. doi: 10.1016/j.jfma.2018.08.011

48.  Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107(7):1079–1087. doi: 10.1038/ajg.2012.60

49.  Madoff SE, Urquiaga M, Alonso CD, Kelly CP. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.Anaerobe . 2020;61:102098. doi: 10.1016/j.anaerobe.2019.102098

50.  Hvas CL, Dahl Jørgensen SM, Jørgensen SP, Storgaard M, Lemming L, Hansen MM, Erikstrup C, Dahlerup JF. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection.Gastroenterology. 2019;156(5):1324-1332.e3. doi: 10.1053/j.gastro.2018.12.019

51.   Peng Z, Ling L, Stratton CW, Li C, Polage CR, Wu B, Tang YW. Advances in the diagnosis and treatment of Clostridium difficile infections. Emerg Microbes Infect. 2018;7(1):15. doi: 10.1038/s41426-017-0019-4

52.  Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Dobebe S, Tacconelli E. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(9):990–1001. doi: 10.1016/S1473-3099(17)30325-0

53.  Moore SC. Clostridium difficile: more challenging than ever. Crit Care Nurs Clin North Am. 2018;30(1):41-53. doi: 10.1016/j.cnc.2017.10.004

54.  Ивашкин В.Т., Абдулганиева Д.И., Алексеенко С.А., Горелов А.В., Захарова И.Н. и соавт. Практические рекомендации Научного сообщества по содействию клиническому изучению микробиома человека (НСОИМ) и Российской гастроэнтерологической ассоциации (РГА) по применению пробиотиков, пребиотиков, синбиотиков и обогащенных ими функциональных пищевых продуктов для лечения и профилактики заболеваний гастроэнтерологического профиля у детей и взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(2):65-91. doi: 10.22416/1382-4376-2021-31-2-65-91

55.  Lau C.S., Chamberlain R.S. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27-37. doi: 10.2147/IJGM.S98280

56. Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, Simon MS, Evans AT. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology. 2017;152(8):1889–1900. doi: 10.1053/j.gastro.2017.02.003

57.  Valdés-Varela L, Gueimonde M, Ruas-Madiedo P. Probiotics for Prevention and Treatment of Clostridium difficile Infection. Adv Exp Med Biol. 2018;1050:161-176. doi: 10.1007/978-3-319-72799-8_10

58.   Gaisawat MB, MacPherson CW, Tremblay J, Piano A, Iskandar MM, Tompkins TA, Kubow S. Probiotic Supplementation in a Clostridium difficile-Infected Gastrointestinal Model Is Associated with Restoring Metabolic Function of Microbiota. Microorganisms. 2020; 8(1):60. doi: 10.3390/microorganisms8010060

59.  Lacotte PA, Simons A, Bouttier S, Malet-Villemagne J, Nicolas V, Janoir C. Inhibition of In Vitro Clostridioides difficile Biofilm Formation by the Probiotic Yeast Saccharomyces boulardii CNCM I-745 through Modification of the Extracellular Matrix Composition. Microorganisms. 2022;10(6):1082. doi: 10.3390/microorganisms10061082

60.  Kelly CP, Chong- Nguyen C, Palmieri LJ, Pallav K, Dowd SE, Humbert L. et al. Saccharomyces boulardii CNCM I-745 modulates the fecal bile acids metabolism during antimicrobial therapy in healthy volunteers. Front. Microbiol. 2019;10:336. doi: 10.3389/fmicb.2019.00336.

61.  Kaźmierczak-Siedlecka K, Ruszkowski J, Fic M, Folwarski M, Makarewicz W. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases. Current Microbiology. 2020;77(9):1987-1996. doi: 10.1007/s00284-020-02053-9.

62.  Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst. Rev. 2017;12(12):CD006095. doi: 10.1002/14651858.CD006095.pub4

63. Wombwell E, Patterson ME, Bransteitter B, Gillen LR. The Effect of Saccharomyces boulardii Primary Prevention on Risk of Hospital-onset Clostridioides difficile Infection in Hospitalized Patients Administered Antibiotics Frequently Associated With C. difficile Infection. Clin Infect Dis. 2021;73(9):2512-2518. doi: 10.1093/cid/ciaa808

64. Maraolo AE, Mazzitelli M, Zappulo E, Scotto R, Granata G, Andini R et al. Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis. Antibiotics (Basel). 2022;11(2):183. doi: 10.3390/antibiotics11020183

65.  Tariq R, Laguio-Vila M, Waqas Tahir M, Orenstein R, Pardi DS, Khanna S. Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2021;14:1756284821994046. doi: 10.1177/1756284821994046